Dr. Tabas, Richard J. Stock Professor of Medicine, Columbia University, completed his M.D./Ph.D. at Washington University and his clinical training at Columbia. His research has focused on the integrated area of cardiometabolic disease, where he has elucidated signaling pathways in macrophages that contribute to atherosclerosis and in hepatocytes that contribute to type 2 diabetes (T2D) and metabolic dysfunction-associated steatohepatitis (MASH). His papers have appeared in Cell, Nature, Science, Nature Cell Biology, Cell Metabolism, Journal of Clinical Investigation, PNAS, and other top journals, and he served on Science's Board of Reviewing Editors from 2011-2023. Dr. Tabas has patents related to atherosclerosis, T2D therapy, and MASH, and he is co-founder of Tabomedex Biosciences, which is developing drugs for these disorders. His awards include election to ASCI/AAP; AHA Established Investigator Award; Columbia University Lamport Award and Irene & Arthur Fishberg Prize; AHA/ATVB Council Special Recognition Award; Washington University Alumni Achievement Award; Society of Leukocyte Biology Bonazinga award, which is the society's highest honor for excellence in leukocyte biology research; Harrington Discovery Institute Innovator-Scholar Award; the AHA Ross Lectureship Award; Keynote lecturer for the 2019 Gordon Research Conference on Phagocytosis; 2019 Dean's Distinguish Lecture, Columbia University Medical Center; 2019 Hugh Sinclair Memorial Lecture, British Atherosclerosis Society; 2020 Journal of Lipid Research Award Lecture from the Deuel Conference on Lipids, the 2021 Irene and Arthur Fishberg Prize, Columbia University; and the Keynote lecture at the 2025 Donald Fredrickson Lipid Research Conference. Dr. Tabas has been supported by multiple NIH R01/P01 grants without interruption for the last 30 years, including an R35 Outstanding Investigator Award from the NHLBI.